Abstracts Archive - Page 1197 of 2425 - ACR Meeting Abstracts

Abstract Number: 2888 • 2018 ACR/ARHP Annual Meeting
Concomitant Csdmards Influence Clinical Response to TNF Inhibitors Only in Overweight Patients with Axial Spondyloarthritis
Borja Hernández-Breijo¹, Victoria Navarro-Compán¹, Ana Martínez¹, Andrea Jochems¹, Alejandro Villalba², Diana Peiteado³, Eva L. Kneepkens⁴, Gerrit Wolbink⁴, Theo Rispens⁵, Dora Pascual-Salcedo¹, Alejandro Balsa¹ and Chamaida Plasencia¹, ¹Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, Reade, Amsterdam, Netherlands, ⁵Immunopathology, Sanquin Research, Amsterdam, Netherlands
Background/Purpose: In patients with axial spondyloarthritis (axSpA), the use of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), such as methotrexate (MTX) and sulfasalazine (SSZ), as well…
Abstract Number: 2889 • 2018 ACR/ARHP Annual Meeting
Inhibition of Radiographic Progression and Correlation with Changes in Composite Indices of Disease Activity in Patients with Active Psoriatic Arthritis Treated with Intravenous Golimumab, As Measured in a Phase III Trial
Philip J. Mease¹, Shelly Kafka², Soumya D Chakravarty³, Diane D. Harrison⁴, Kim Hung Lo⁴, Stephen Xu⁴, Elizabeth C Hsia⁵ and Arthur Kavanaugh⁶, ¹Swedish Medical Centre and University of Washington, Seattle, WA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Reseach & Development, LLC/ U of Pennsylvania School of Medicine, Spring House/Philadelphia, PA, ⁶University of California, San Diego, School of Medicine, La Jolla, CA
Background/Purpose: GO-VIBRANT is a Phase 3 trial of intravenous (IV) golimumab (GLM), an anti-tumor necrosis factor alpha (TNFα) monoclonal antibody, in adult patients (pts) w/…
Abstract Number: 2890 • 2018 ACR/ARHP Annual Meeting
Effect of Tapering of Tumor Necrosis Factor Inhibitor on Achieving Inactive Disease in Axial Spondyloarthritis Based on the ‘Treat-to-Target’ Strategy: A Nationwide Prospective Cohort Study
Jun Won Park¹, Min Jung Kim¹, Hyoun-Ah Kim², Kichul Shin³, Yong-Beom Park⁴, Yeong Wook Song⁵ and Eun Young Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ³Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ⁴Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South)
Background/Purpose: Although recent treatment guideline of axial spondyloarthritis (axSpA) by the European League Against Rheumatism (EULAR) recommended that tapering of tumor necrosis factor inhibitor (TNFi)…
Abstract Number: 2891 • 2018 ACR/ARHP Annual Meeting
Eligibility Criteria for TNFi Therapy in Axial Spa: Going Beyond Basdai
José Marona^1,2, Alexandre Sepriano^2,3, Santiago Rodrigues Manica^1,2, Fernando Pimentel-Santos^1,2, Ana Filipa Mourão^1,2, Nélia Gouveia², Jaime Cunha Branco^1,2, Filipe Vinagre⁴, Raquel Roque⁴, João Rovisco⁵, Mary Lucy Marques⁵, José Tavares Costa⁶, Joana Leite Silva⁶, Helena Santos⁷, Nathalie Madeira⁷, Elsa Vieira-Sousa^8,9, Ana Rita Machado¹⁰, Miguel Bernardes¹¹, Raquel Ferreira¹¹ and Sofia Ramiro^2,12,13, ¹Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ²CEDOC, NOVA Medical School, Lisbon, Portugal, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ⁵Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁶Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ⁷Rheumatology, Instituto Português de Reumatologia, Lisbon, Portugal, ⁸Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE, Lisbon, Portugal, ⁹Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal, ¹⁰Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, Lisboa, Portugal, ¹¹Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ¹²Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands, ¹³Department of Rheumatology, Zuyderland Medical Center, Heerlen, Netherlands
Background/Purpose: A BASDAI ≥4 has often been required to start TNF inhibitors (TNFi) therapy in patients with axial SpA (axSpA). However, this cut-off of high…
Abstract Number: 2892 • 2018 ACR/ARHP Annual Meeting
Safety and Immune Response of a Live Attenuated Herpes Zoster Vaccine in Patients with Systemic Lupus Erythematosus (SLE): A Randomized Placebo-Controlled Trial
Chi Chiu Mok¹, Kwok Hung Chan², Ling Yin Ho³ and Patrick Chiu Yat Woo², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Microbiology, University of Hong Kong, Hong Kong, Hong Kong, ³Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To evaluate the safety and immune response of a live attenuated herpes zoster (HZ) vaccine in patients with SLE by a randomized placebo-control trial…
Abstract Number: 2893 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes and Response to Anti-Thrombotic Treatment Among Patients with Concomitant Lupus Nephritis and Thrombotic Microangiopathy: A Multicenter Cohort Study
Savino Sciascia¹, Jinoos Yazdany², Maria Jose Cuadrado³, Massimo Radin⁴, Maria Dall'Era², Ishita Aggarwal⁵, Roberta Fenoglio⁶, Antonella Barreca⁷, Mauro Papotti⁷, Irene Cecchi⁸, Elena Rubini⁹, Karen Schreiber¹⁰ and Dario Roccatello⁶, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ²University of California, San Francisco, San Francisco, CA, ³Clinica Universidad de Navarra, Madrid, Spain, ⁴Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Medicine, Santa Clara Valley Medical Center, San Jose, CA, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁷University of Turin, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ¹⁰Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom
Background/Purpose: Renal vascular involvement is an important prognostic marker of lupus nephritis (LN). Among patients with various vascular changes, individuals with thromboticmicroangiopathy (TMA) present with…
Abstract Number: 2894 • 2018 ACR/ARHP Annual Meeting
Psychosis in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
John G. Hanly¹, Qiuju Li², Li Su³, Murray Urowitz⁴, Caroline Gordon⁵, Sang-Cheol Bae⁶, Juanita Romero-Díaz⁷, Jorge Sanchez-Guerrero⁴, Sasha Bernatsky⁸, Ann E. Clarke⁹, Daniel J. Wallace¹⁰, David A. Isenberg¹¹, Anisur Rahman¹², Joan T. Merrill¹³, Paul R. Fortin¹⁴, Dafna D Gladman¹⁵, Ian N. Bruce¹⁶, Michelle Petri¹⁷, Ellen M. Ginzler¹⁸, Mary Dooley¹⁹, Kristján Steinsson²⁰, Rosalind Ramsey-Goldman²¹, Asad A Zoma²², Susan Manzi²³, Ola Nived²⁴, Andreas Jönsen²⁴, Munther A Khamashta²⁵, Graciela S. Alarcón²⁶, Ronald F van Vollenhoven²⁷, Cynthia Aranow²⁸, Meggan Mackay²⁸, Guillermo Ruiz-Irastorza²⁹, Manuel Ramos-Casals³⁰, S. Sam Lim³¹, Murat Inanc³², Kenneth C. Kalunian³³, Søren Jacobsen³⁴, Christine A. Peschken³⁵, Diane L. Kamen³⁶, Anca Askanase³⁷, Chris Theriault³⁸ and Vernon Farewell³⁹, ¹Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ²MRC Biostatistics Unit, Cambridge, United Kingdom, ³Nova Scotia Rehab Site, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁴University of Toronto Lupus Research Program, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁸Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁹Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹⁰Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹¹University College London, London, United Kingdom, ¹²Rayne Institute, University College London, London, United Kingdom, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ¹⁵Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ¹⁷Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ¹⁹Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ²⁰Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²¹FSM, Northwestern University, Chicago, IL, ²²Lanarkshire Center for Rheumatology, Hairmyres Hospital, East Kilbride, East Kilbride, Scotland, United Kingdom, ²³Autoimmunity Institute and Medicine Institute, Allegheny Health Network, Pittsburgh, PA, ²⁴Rheumatology, Lund University, Department of Clinical Sciences, Lund, Sweden, ²⁵Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ²⁶University of Alabama at Birmingham, Birmingham, AL, ²⁷Unit for clinical therapy research (ClinTRID), Karolinska Institute, Stockholm, Sweden, ²⁸The Feinstein Institute for Medical Research, Manhasset, NY, ²⁹Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ³⁰Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ³¹Emory University School of Medicine, Atlanta, GA, ³²Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³³Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ³⁴Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁵RR 149G, University of Manitoba, Winnipeg, MB, Canada, ³⁶Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³⁷Rheumatology, Columbia University, College of Physician and Surgeons, New York, NY, ³⁸Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ³⁹Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Psychosis, one of the rarer neuropsychiatric (NP) events in lupus patients, features in both the ACR and Systemic Lupus International Collaborating Clinics (SLICC) classification…
Abstract Number: 2895 • 2018 ACR/ARHP Annual Meeting
Effect of Vitamin D on Serum Markers of Bone Turnover in SLE in a Randomized Controlled Trial
Sara K. Tedeschi¹, Cynthia Aranow², Diane L. Kamen³, Meryl S. LeBoff⁴, Betty Diamond² and Karen Costenbader⁵, ¹Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ²The Feinstein Institute for Medical Research, Manhasset, NY, ³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁴Division of Endocrinology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Bone health in SLE is adversely affected by vitamin D deficiency, inflammatory cytokines including interferon (IFN)-α, and glucocorticoid use. We tested the hypothesis that…
Abstract Number: 2896 • 2018 ACR/ARHP Annual Meeting
Increased Mortality Among Patients with Systemic Lupus Erythematosus after Hydroxychloroquine Discontinuation
April Jorge¹, Na Lu^2,3, Eric C. Sayre³, Hamid Tavakoli⁴, Natalie McCormick⁵, John M. Esdaile^3,6, Mary DeVera⁵, Hyon K. Choi¹ and J. Antonio Avina-Zubieta⁷, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, ⁵Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁶Department of Medicine, Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁷Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is near-universally recommended for patients with SLE. Use of this medication has previously been associated with a substantial survival benefit among SLE…
Abstract Number: 2897 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Levels Show Significant Trend Test for Risk of Retinopathy
Michelle Petri¹, Marwa Elkhalifa², Daniel Goldman¹, Laurence S Magder³ and Mandeep Singh⁴, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, ⁴Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hydroxychloroquine (HCQ) retinopathy after 10 years or more of use is more frequent than previously appreciated. This led to new ophthalmology guidelines that changed…
Abstract Number: 2898 • 2018 ACR/ARHP Annual Meeting
Increased Frequency of Circulating CD4+CXCR5-PD1hi Peripheral Helper T (cTph) Cells in Patients with Seropositive Early Rheumatoid Arthritis (RA)
Paula Fortea-Gordo¹, Laura Nuño², Alejandro Villalba², Diana Peiteado³, Irene Monjo⁴, Paloma Sanchez-Mateos⁵, Amaya Puig-Kröger⁶, Alejandro Balsa¹ and Maria Eugenia Miranda-Carus¹, ¹Rheumatology, Hospital La Paz - IdiPAZ, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁵Immunology, Hospital Gregorio Marañon, Madrid, Spain, ⁶Immuno-oncology, Hospital Gregorio Marañon, Madrid, Spain
Background/Purpose: A novel population of CD4+ T cells with B cell helping capacity has been described in the synovial tissues and peripheral blood of seropositive…
Abstract Number: 2899 • 2018 ACR/ARHP Annual Meeting
Sustained Drug-Free Remission in Early RA Following Methotrexate-Based Strategy: Role of the JAK-STAT Pathway
Xavier M Teitsma¹, Johannes W. G. Jacobs², Arno N Concepcion³, Attila Pethö-Schramm⁴, Michelle EA Borm⁵, Jacob van Laar¹, Johannes W. J. Bijlsma⁶ and Floris PJG Lafeber¹, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴F. Hoffmann-La Roche, Basel, Switzerland, ⁵Roche Nederland BV, Woerden, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: We previously identified several co-expressed genes associated with achieving sustained drug-free remission (sDFR) following a methotrexate (MTX)-based strategy in early rheumatoid arthritis (RA).1 The…
Abstract Number: 2900 • 2018 ACR/ARHP Annual Meeting
Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells
Judith Ashouri¹, Lih-Yun Hsu¹, Dmitry Rychkov², Marina Sirota², Lisa Lattanza³, Eric Hansen³, Julie Zikherman¹ and Arthur Weiss¹, ¹Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, ³Orthopedic Surgery, University of California, San Francisco, San Francisco, CA
Background/Purpose: The inability to identify relevant arthritogenic CD4 T cells in patients and in murine disease models has limited our understanding of disease initiating events…
Abstract Number: 2901 • 2018 ACR/ARHP Annual Meeting
Sputum Neutrophils from Individuals at-Risk for RA Demonstrate Increased Citrullinated Histone H3 Containing Neutrophil Extracellular Traps That Correlate with Sputum Anti-Cyclic Citrullinated Peptide Antibody Levels
Yuko Okamoto¹, Nickie L. Seto², Mariana J. Kaplan², Ashley Visser¹, Jill M. Norris³, Kevin D. Deane¹, V. Michael Holers⁴ and M. Kristen Demoruelle¹, ¹Division of Rheumatology, University of Colorado Denver, Aurora, CO, ²Systemic Autoimmunity Branch, NIAMS/NIH, Bethesda, MD, ³Department of Epidemiology, Colorado School of Public Health, Aurora, CO, ⁴Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Our group previously demonstrated that anti-citrullinated (cit) protein antibodies (ACPA) in the sputum correlate with remnants of neutrophil extracellular traps (NETs) in RA-free subjects…
Abstract Number: 2902 • 2018 ACR/ARHP Annual Meeting
Antibodies to PAD4 Drive Monocyte Activation and Differentiation into Osteoclast-like Cells
Pooja Naik¹, Jing Shi², Felipe Andrade³ and Erika Darrah⁴, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Department of Medicine/Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Agonistic antibodies to Peptidylarginine Deiminase 4 (PAD4) are hallmarks of a severe form of rheumatoid arthritis (RA) characterized by the most erosive joint damage…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].